Nuvation Bio Inc. NUVB
Regular-session close
Pre-market · Nov 20, 7:59 AM ET
- YTD
- -57.48%
- 1 year
- -45.65%
5D -0.17 (-4.27%)
- Market cap
- 1.34B
- Revenue (ttm)
- 201.73M
- Profit margin
- -67.38%
- EPS (ttm)
- -0.39
- Shares out
- 352.02M
- Forward P/E
- -47.63
- YTD return
- -57.48%
- 1-year return
- -45.65%
- 50-day average
- 4.96
- 200-day average
- 5.30
- Volume
- 9.92M
- Avg volume
- 5.23M
- Open
- 3.77
- Previous close
- 3.78
- Day's range
- 3.71 – 4.03
- 52-week range
- 3.71 – 9.75
- Beta
- 1.73
- Analysts
- Strong Buy
- Price target
- 12.45 (+226.9%)
- Earnings date
- Mar 1, 2027
Key statistics
- Enterprise value
- 1.14B
- Price / sales
- 6.67
- Price / book
- 5.90
- Revenue growth
- 242.60%
- Free cash flow
- -76.06M
- Total cash
- 663.37M
- Total debt
- 468.12M
- Return on equity
- -49.09%
- Short % of float
- 28.82%
Fundamental scorecard
5 of 25 checks passed on NUVB’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 7.00
- Target (mean)
- 12.45
- Target (high)
- 21.00
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.095.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -0.11 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.12374 | -0.12 | 0.00 | +3.02% |
| Aug 6, 2026 | Jun 30, 2026 | -0.14166 | -0.15 | -0.01 | -5.89% |
| May 4, 2026 | Mar 31, 2026 | -0.02804 | 0.01 | +0.04 | +135.66% |
| Mar 2, 2026 | Dec 31, 2025 | -0.11 | -0.11 | 0.00 | 0.00% |
| Nov 3, 2025 | Sep 30, 2025 | -0.17 | -0.16 | +0.01 | +5.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 30, 2026 | Citigroup | init | — | Buy |
| Sep 16, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 21, 2026 | Cantor Fitzgerald | init | — | Overweight |
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nuvationbio.com
News
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $21 Price Target
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
ACT Capital Partners L.P. Buys 579,500 Shares of Nuvation Bio Inc. $NUVB
12 Health Care Stocks Moving In Thursday's After-Market Session RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17
Nuvation Bio Q3 2026 Earnings Call Transcript Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate
Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting
Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
Your note
Sign in to keep a note on NUVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANLEY DAVID C | Chief Technology Officer | Conversion of Exercise of derivative security | Nov 18, 2025 | 24,000 |
| HATTERSLEY GARY | Officer | Conversion of Exercise of derivative security | Aug 18, 2026 | 0 |
| HUNG DAVID T | Chief Executive Officer | Purchase | Jun 15, 2025 | 59,281,100 |
| LIU DONGFANG | Officer | Conversion of Exercise of derivative security | Apr 16, 2026 | 18,000 |
| MAKUNJE MOSES | Officer | Stock Award(Grant) | Feb 26, 2026 | 68,137 |
| MARKEL STACY | Officer | Conversion of Exercise of derivative security | Jun 22, 2026 | 32,591 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.92% | 52,668,484 | 200.67M | Sep 29, 2026 |
| Blackrock Inc. | 8.19% | 28,924,444 | 110.20M | Sep 29, 2026 |
| Decheng Capital LLC | 7.35% | 25,954,439 | 98.89M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.44% | 12,152,903 | 46.30M | Sep 29, 2026 |
| Laurion Capital Management, LP | 2.18% | 7,697,272 | 29.33M | Sep 29, 2026 |
| State Street Corporation | 2.15% | 7,596,209 | 28.94M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.02% | 17,725,175 | 67.53M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.51% | 8,849,329 | 33.72M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.85% | 6,523,172 | 24.85M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.41% | 4,993,377 | 19.02M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.29% | 4,568,601 | 17.41M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.97% | 3,423,823 | 13.04M | Sep 29, 2026 |
